Dietrich John Pauls - 16 Aug 2021 Form 4 Insider Report for DiaMedica Therapeutics Inc. (DMAC)

Role: President and CEO, Director
Signature: /s/ Amy Culbert, attorney-in-fact
Issuer symbol: DMAC
Transactions as of: 16 Aug 2021
Net transactions value: +$15,700
Form type: 4
Filing time: 16 Aug 2021, 16:19:26 UTC
Previous filing: 29 Jul 2021
Next filing: 02 Jun 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	DMAC	Voting Common Shares, no par value per share	Purchase	$15,700	+5,000	+16%	$3.14	35,804	16 Aug 2021	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.12 to $3.15, inclusive. The reporting person undertakes to provide to DiaMedica Therapeutics Inc., any security holder of DiaMedica Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4.
F2	Includes 1,749 voting common shares issuable upon settlement of deferred share units granted under the DiaMedica Therapeutics Inc. Deferred Share Unit Plan.

Content

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.12 to $3.15, inclusive. The reporting person undertakes to provide to DiaMedica Therapeutics Inc., any security holder of DiaMedica Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4.

Includes 1,749 voting common shares issuable upon settlement of deferred share units granted under the DiaMedica Therapeutics Inc. Deferred Share Unit Plan.